Will the FDA Approve the First Multi-Cancer Blood Test? The Vote That Could Change Cancer Screening Forever

 Will the FDA Approve the First Multi-Cancer Blood Test? The Vote That Could Change Cancer Screening Forever

**By a Market Analyst & Business News Writer | September 23, 2026**

---

## The Vote That Could Save — Or Cost — Tens of Thousands of Lives

Let me tell you about a moment happening right now that could be remembered as the day cancer screening changed forever.

This morning, a panel of independent medical experts is gathering at the FDA's White Oak campus in Silver Spring, Maryland. They're not there to talk about a new drug or a new device. They're there to answer a question that millions of Americans are desperate to know: **Can a simple blood draw detect cancer anywhere in your body — and should the government let it be sold as a screening test?**

The test is called **Galleri**. It's made by a company called **Grail**. And if the FDA's Molecular and Clinical Genetics Panel votes to recommend approval today, Galleri would become the **first multi-cancer early detection test ever approved** by the U.S. government.

The panel will hear from Grail, FDA officials, and the public before voting on a recommendation. The FDA often follows the advice of its advisory panels but is not legally bound to do so. The meeting runs from 9 a.m. to 6 p.m. Eastern Time.

If Galleri gets the green light, it could trigger Medicare reimbursement for a test that currently costs **$949 out of pocket**. It could open the door for hundreds of other companies chasing the same promise — dozens of tests now competing for a global market estimated to reach **$2.9 billion by 2030**.

But if the panel votes no — or votes yes with major caveats — the entire field could be set back years.

This is the story of what's at stake. And why it matters to you, whether you're an investor, a patient, or someone who just wants to know if there's a better way to catch cancer early.

---

## What Is Galleri? The Science Behind the Promise

Let me break down how this test works — no medical degree required.

### The Blood Draw That Could Change Everything

Galleri uses a simple blood draw. That's it. No colonoscopy. No mammogram. No invasive procedure. Just a needle, a vial, and a few weeks of waiting.

The science behind it is remarkable. When cancer cells grow in your body, they die. And when they die, they release tiny fragments of DNA into your bloodstream. These fragments — called **cell-free DNA** — carry chemical marks called **methylation patterns** that can distinguish cancer DNA from normal DNA.

Grail's machine-learning algorithm analyzes those patterns and can detect the presence of cancer — and even predict where in the body the cancer originated.

### The Claims

Grail says Galleri can detect **up to 50 different types of cancer** from a single blood sample. That includes many cancers that have **no routine screening tests at all** — pancreatic, ovarian, liver, bile duct, and others that are often diagnosed only after symptoms appear, when it's often too late.

The company positions Galleri as **complementary** to standard screenings like mammograms and colonoscopies, not a replacement.

And here's the number that hits home: **More than 70% of cancer deaths in the U.S. come from cancers that have no recommended screening test**. When you factor in real-world adherence rates, that number rises above **80%**.

That's the gap Galleri is trying to close. And it's why doctors, patients, and investors are watching today's vote so closely.

---

## The Data: Impressive Numbers, Unmet Endpoints

Now let's get into the numbers. Because this is where the story gets complicated.

The FDA committee will review two major clinical studies conducted by Grail:

**PATHFINDER 2**: A North American study of **35,878 adults aged 50 and older**, the largest interventional MCED study ever conducted on the continent.

**NHS-Galleri**: A massive UK study involving **more than 140,000 patients** in the National Health System.

### The PATHFINDER 2 Data: Best-Case Numbers

The results, published Tuesday in Nature Medicine, are genuinely impressive on several fronts:

- **Specificity**: 99.64% — meaning the test rarely produces false positives

- **Negative predictive value**: 99.2% — if the test says you don't have cancer, you almost certainly don't

- **Positive predictive value**: 60.3% — if the test says you do have cancer, there's a 60% chance it's right

- **Cancer signal origin prediction accuracy**: 91.3% — the test does a remarkably good job of predicting where the cancer is located

- **Episode sensitivity for 12 major cancers**: 69.8% — the test catches about 70% of the 12 most common cancers

When added to standard screening recommendations, the test increased the number of cancers detected **6.5-fold**. Nearly half of the cancers detected by the blood test were diagnosed at stages 1 through 2, and nearly three-quarters were diagnosed at stages 1 through 3 — when curative treatment is more often possible.

Seventy percent of the cancers detected were types that currently **lack national screening recommendations**.

### The Big Problem: It Didn't Hit Its Primary Endpoints

Here's where the story gets messy.

**Neither the NHS study nor the PATHFINDER 2 trial met their primary endpoints.**

The NHS study was designed to show that Galleri could reduce overall cancer mortality. **It didn't.** It also failed to reduce the combined number of Stage III and Stage IV cancers.

This is a significant problem. In clinical trials, primary endpoints matter. They're what the study is actually designed to measure. Missing them is not a small issue.

Grail later clarified that when looking at **Stage IV cancer diagnoses alone** — not combined with Stage III — there was a decrease over the three-year study period. The company argues this suggests the test is shifting cancer diagnoses to earlier stages.

But the FDA isn't just evaluating whether the test can detect cancer. It's evaluating whether the evidence supports calling Galleri an **“early detection” test** — and whether that claim justifies use in marketing.

### The Sensitivity Problem

There's another concern that the headline numbers don't fully capture: **sensitivity**.

Across **all cancers**, the episode sensitivity of Galleri was just **39.3%**. That means for every 100 people who actually had cancer, Galleri would miss about 60 of them.

For the 12 most common cancers, sensitivity jumped to **69.8%**. But for the dozens of other cancers Galleri claims to detect, sensitivity is much lower.

This raises a critical question: **If the test misses 60% of cancers, is it actually useful as a screening tool?** Or does it create a false sense of security that leads patients to skip other tests?

The FDA is clearly concerned about this. The agency has asked the committee to consider the **harms from false results** — both false negatives (missing a cancer that exists) and false positives (flagging a cancer that doesn't).

The agency is even considering requiring Grail to include caveats in its marketing, such as warnings that a negative result does not rule out cancer and a positive result does not confirm it.

---

## The FDA's Signal: A Surprising Vote of Confidence

Despite the unmet endpoints and sensitivity concerns, the FDA's own staff reviewers have signaled **cautious optimism**.

In briefing documents posted Monday ahead of the advisory meeting, FDA reviewers **did not raise major concerns** about Galleri's accuracy and safety. The agency had **no outstanding questions** for the external panel on analytical performance, study design, and primary safety analyses.

The FDA said it wanted to discuss whether the evidence supports Galleri's characterization as an **“early detection” test**.

The market's reaction was immediate. Grail's stock **surged 33%** on Monday after the documents were posted, and another **35%** on Tuesday. Shares closed at **$108.52**.

Analysts described the FDA briefing documents as **“amicable”** to approval. Piper Sandler's David Westenberg said he expects a **favorable vote**.

"This is constructive for Grail," Westenberg said.

---

## The Medicare Factor: Why This Vote Is Worth Billions

If you want to understand why this vote matters so much — and why Grail's stock has been on a roller-coaster ride all year — you need to understand the **Medicare connection**.

### The Law That Changes Everything

In February 2026, Congress passed the **Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act**. President Trump signed it into law. The legislation establishes Medicare coverage for FDA-approved MCED screening tests **beginning in 2028**.

Here's how it works:

- Medicare coverage is limited to **one test every 11 months**

- There's an **age-based eligibility limit** that starts at 68 in 2028 and increases by one year annually

- Reimbursement rates through 2030 are set at **parity with current multi-target stool DNA tests** (like Cologuard)

In other words: **FDA approval is the key that unlocks the Medicare vault.**

Currently, Galleri costs **$949** and is rarely covered by insurance. Most people who take it pay out of pocket.

But if the FDA approves Galleri, and CMS follows through with coverage, every American over 68 could potentially get this test covered by Medicare.

That's a massive market. And it's why Grail — and every other MCED company — has been lobbying so hard for this moment.

### The Grail Roller-Coaster

Grail's stock has been on a wild ride in 2026:

- **Started trading at $13.95** after its spin-off from Illumina in June 2024

- **Hit a record high of $116.06** on January 22, 2026

- **Plunged more than 20%** in February after the NHS trial failed to show significant benefit

- **Traded as low as $47.56** in April

- **Now trading at $108.52** after the FDA documents leaked

The company brought in **$136.8 million in U.S. revenue** in 2025. It has sold more than **420,000 test kits**.

But here's the thing: Grail is **not profitable**. It's burning cash. And its future depends entirely on whether it can convince the FDA — and then Medicare — that Galleri is worth paying for.

---

## The Competition: Who Else Is Chasing the Same Prize?

Grail isn't alone in this race. And the outcome of today's vote could set the bar for the entire industry.

### Exact Sciences (Now Owned by Abbott)

Exact Sciences, the company behind Cologuard, launched its own multi-cancer blood test called **Cancerguard** in 2025. It's priced at **$689** — cheaper than Galleri — and is also available as a laboratory-developed test (LDT) under CLIA regulations.

Like Galleri, Cancerguard is **not FDA-approved**. But Exact Sciences is pursuing approval, and the company has been acquired by **Abbott Laboratories**, giving it enormous resources to compete.

The researcher who helped develop Cancerguard's underlying technology? **Cristian Tomasetti**, now director of City of Hope cancer center's early detection division. He's been publicly supportive of Galleri's FDA bid, calling it a **“new era for early cancer detection”**.

### Dozens of Other Players

A recent JAMA article noted that the commercial market for multicancer detection tests has grown to **more than 24 companies**.

They include:

- **CancerSEEK** (Johns Hopkins)

- **OncoSeek** (AI-powered, high sensitivity for symptomatic patients)

- Various methylation-based and fragmentomics-based tests

None of them have FDA approval. Galleri is simply the furthest along in the process. That's why it's being watched as a **bellwether for the entire industry**.

---

## What the Experts Are Saying

The debate over Galleri has divided the medical community. Here are the key voices:

### The Optimists

**Cristian Tomasetti, City of Hope**: "To me, it doesn't mean that the study — in terms of substance — failed to show evidence of what [multi-cancer detection tests] can actually do." He argues the missed endpoints are a product of how the studies were designed rather than evidence the technology falls short, noting that screening trials generally need longer timeframes before mortality benefits become measurable.

**Nima Nabavizadeh, OHSU Knight Cancer Institute**: "We screen for just five cancers, yet the ones we can't screen for cause up to 70% of cancer deaths in this country; that's the gap this blood test helps close. It finds many of these cancers while they're still asymptomatic and localized, when cure is still possible".

### The Skeptics

**The FDA's questions to the committee**: The agency wants to know whether the evidence supports calling Galleri an "early detection" test — and whether harms from false results are being adequately addressed.

**Unnamed researchers** quoted by NPR: The interpretation of the studies "has been somewhat controversial" — a diplomatic way of saying that the evidence isn't as clear-cut as Grail's marketing suggests.

---

## Frequently Asked Questions (FAQs)

### Q1: What is Galleri?

Galleri is a multi-cancer early detection blood test developed by Grail. It analyzes cell-free DNA in the bloodstream to detect cancer-specific methylation patterns and predict where the cancer originated. Grail says it can detect up to 50 types of cancer from a single blood draw.

### Q2: Why is the FDA voting on this test now?

Grail submitted a **Premarket Approval (PMA) application** to the FDA on January 29, 2026. The FDA expedited its review based on the test's promise. The Molecular and Clinical Genetics Panel is meeting September 23, 2026, to review the evidence and vote on whether to recommend approval.

### Q3: What are the key clinical trial results?

PATHFINDER 2 (35,878 North American participants) showed:

- Specificity of 99.64%

- Sensitivity of 39.3% across all cancers, 69.8% for 12 major cancers

- Cancer detection rate of 0.54%

- Positive predictive value of 60.3%

- 6.5-fold increase in cancer detection when added to standard screening

The NHS-Galleri study (140,000+ participants) **did not meet its primary endpoint** of reducing overall mortality or combined Stage III/IV cancers, though Stage IV diagnoses alone decreased over three years.

### Q4: How much does Galleri cost?

Galleri lists at **$949 per test**. Most insurance plans do not currently cover it. If FDA-approved, Medicare coverage could begin in 2028 under the Nancy Gardner Sewell MCED Screening Coverage Act.

### Q5: What happens if the FDA panel votes yes?

A favorable vote would be a strong signal that the FDA is likely to approve Galleri. Approval would:

- Trigger Medicare reimbursement starting in 2028

- Set a regulatory precedent for other MCED tests

- Potentially open the door for private insurance coverage

- Validate the entire multi-cancer early detection industry

### Q6: What happens if the panel votes no?

A negative vote wouldn't necessarily kill Galleri — the FDA isn't bound by the panel's recommendation. But it would signal significant concerns about the evidence. Grail's stock would likely plummet, and other MCED companies would face a much harder path to approval.

### Q7: Is this test a replacement for mammograms or colonoscopies?

No. Grail explicitly states that Galleri should be **additive** to standard screenings — used alongside them, not instead of them. The company says it's meant to catch cancers that currently have no routine screening tests.

### Q8: How does this affect investors?

Grail (ticker: GRAL) is the most directly affected stock. The company's market cap and future revenue depend entirely on FDA approval and Medicare coverage. Other companies in the MCED space — including Abbott (which owns Exact Sciences) and companies developing liquid biopsy technologies — could also see significant stock movement based on the vote.

### Q9: Should I get the Galleri test?

That's a decision between you and your doctor. The test is available now as a laboratory-developed test (LDT) under CLIA regulations, meaning it's legal to sell but hasn't undergone FDA review. The $949 cost is typically out of pocket. If you're over 50 and concerned about cancer risk, discuss it with your healthcare provider.

### Q10: What should I watch for next?

The panel's vote (favorable, unfavorable, or with caveats), the FDA's final decision on the PMA application (expected in early 2027), and CMS's implementation of Medicare coverage (beginning 2028).

---

## High-Value Keywords for Content Creators and AdSense Publishers

For bloggers, affiliate marketers, and AdSense publishers covering this story, here are the most profitable keywords to target:

### Tier 1: High CPC ($15+)

| Keyword | Estimated CPC | Search Volume |

|---------|--------------|---------------|

| Multi-cancer blood test FDA approval | $25-$40 | Very High |

| Galleri test cost and coverage | $20-$35 | High |

| Best cancer screening tests 2026 | $18-$30 | High |

| Liquid biopsy stocks to buy | $15-$25 | High |

| MCED test Medicare coverage | $15-$22 | Medium |

### Tier 2: High Volume, Low Competition

| Keyword | Search Volume | Competition |

|---------|--------------|-------------|

| Galleri blood test review | Very High | Low |

| Multi-cancer early detection explained | High | Very Low |

| Is Galleri FDA approved | Very High | Low |

| Grail stock GRAL news | High | Low |

| How accurate is Galleri test | High | Low |

### Tier 3: Long-Tail Money Keywords

- "Should I get the Galleri cancer test"

- "Galleri vs Cancerguard comparison"

- "How to get Medicare coverage for cancer blood test"

- "Multi-cancer blood test clinical trial results"

- "Grail stock forecast after FDA approval"

---

## Conclusion: The Vote That Defines a New Era

The FDA advisory committee's vote today is more than a regulatory formality. It's a **referendum on the future of cancer screening**.

If the panel votes yes, Galleri becomes the first FDA-approved multi-cancer blood test in history. Medicare coverage follows. Hundreds of other companies get a clear regulatory pathway. And millions of Americans gain access to a test that could catch cancer earlier — when it's most treatable.

If the panel votes no, the entire field gets a cold dose of reality. The evidence isn't strong enough. The endpoints weren't met. The harms from false results aren't fully understood.

The truth, as always, lies somewhere in between.

Galleri's data is genuinely impressive on specificity and cancer signal origin prediction. It's less impressive on sensitivity, and the failure to meet primary endpoints in the NHS trial is a legitimate concern.

But here's what the numbers don't capture: the human stories.

The 84-year-old retired physician who took the test and discovered a rare bile duct cancer before he had symptoms. The patients whose cancers were caught at Stage 1 or 2, when cure is still possible. The families who got more time with their loved ones because a blood test flagged something early.

Those stories are why this vote matters. And they're why — whether the panel votes yes or no — the journey toward better cancer screening doesn't end today.

It's just beginning.

---

## Disclaimer

This article is for informational and educational purposes only and does not constitute financial, medical, or investment advice. The information contained herein is based on publicly available sources as of September 23, 2026. Clinical trial data and regulatory decisions are subject to change. The FDA is not bound by advisory committee recommendations. Stock market investments involve risk, including the potential loss of principal. Always consult a qualified financial advisor before making investment decisions and a qualified healthcare provider before making medical decisions. The author does not hold positions in any of the securities mentioned.

---

**Tags**: #Galleri #Grail #MultiCancerBloodTest #MCED #FDA #FDAdvisoryCommittee #CancerScreening #EarlyDetection #LiquidBiopsy #GRAL #StockMarketNews #Investing #BiotechStocks #HealthcareInvesting #CancerDetection #BloodTest #Medicare #CMS #NHSTrial #PATHFINDER2 #ExactSciences #Abbott #Cancerguard #CancerResearch #Oncology #MedicalDevices #PMA #PreMarketApproval #CancerAwareness #HealthTech #Diagnostics #MolecularDiagnostics #CellFreeDNA #Methylation #PrecisionMedicine #PatientCare #FDAApproval #DrugApproval #BiotechNews #MarketAnalysis #FinancialNews